Treatment : To Treat a Certain Type of Advanced Breast Cancer
Dosage : As per Doctor's Prescription
Form : Tablets
Best Before : 36 Months from Manufacturing
Storage : Cool and Dry Place
FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic more...